Prosecution Insights
Last updated: August 17, 2026
Application No. 18/837,494

INSECT, ACARINA AND NEMATODE PEST CONTROL

Non-Final OA §101§102§112
Filed
Aug 09, 2024
Priority
Feb 10, 2022 — EU 22156188.9 +1 more
Examiner
ROZOF, TIMOTHY R
Art Unit
Tech Center
Assignee
Syngenta AG
OA Round
1 (Non-Final)
73%
Grant Probability
Favorable
1-2
OA Rounds
0m
Est. Remaining
97%
With Interview

Examiner Intelligence

Grants 73% — above average
73%
Career Allowance Rate
699 granted / 962 resolved
+12.7% vs TC avg
Strong +24% interview lift
Without
With
+23.9%
Interview Lift
resolved cases with interview
Fast prosecutor
2y 0m
Avg Prosecution
52 currently pending
Career history
995
Total Applications
across all art units

Statute-Specific Performance

§101
2.4%
-37.6% vs TC avg
§103
21.6%
-18.4% vs TC avg
§102
32.5%
-7.5% vs TC avg
§112
25.7%
-14.3% vs TC avg
Black line = Tech Center average estimate • Based on career data from 962 resolved cases

Office Action

§101 §102 §112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION This is a response to Applicant’s communication filed on July 24, 2026. Application No. 18/837,494, is a 371 of PCT/EP2023/053393, filed February 10, 2023, and claims foreign priority to European Patent application No. EP 22156188.9, filed February 10, 2022. Claims 1-20 are pending. Claim Rejections - 35 USC § 102(a)(1) The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claims 1-20 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Sato et al., JP2020/186191 (cited on the August 9, 2024, IDS). Sato disclose seeds or seed treatment compositions, formulations, or concentrates comprising compound (A-1) and at least one other pesticide selected from at least flutolanil (B-104), flubendiamide (B-54) and/or pyraziflumid (B-105), for controlling or preventing damage by insect, acarina, and/or nematode pests and/or fungal pathogens to a plant. See Sato et al., JP ‘191, para. [0079]-[0100], for compositions of (A-1) and formula B (54, 104, and 105); see also Id., para. [0245]-[0248] for the further pesticides relevant to those of formula B; see Id., para. [0007], for composition ratios of first ingredient component A to formula B pesticide component(s); see Id., para. [0185], for seed treatments; see Id. paras. [0196] and [0209], for insecticidal and or antifungal compositions; see Id., para. [0146]-[0148], for formulations and concentrations. Claim Rejections - 35 USC § 112(b) The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. Claims 3, 5, 6, 8, 10, 11, and 20 are rejected under 35 U.S.C. 112(b) as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor regards as the invention. A broad range or limitation together with a narrow range or limitation that falls within the broad range or limitation (in the same claim) may be considered indefinite if the resulting claim does not clearly set forth the metes and bounds of the patent protection desired. See MPEP § 2173.05(c). In the present instance, claims 3, 5, 6, 8, 10, 11 and 20, recite the broad recitation of ratios and rate(s) of application, and the claims also recite the terms “preferably,” “especially,” “more especially” which is the narrower statement of the range/limitation. The claim(s) are considered indefinite because there is a question or doubt as to whether the feature introduced by such narrower language is (a) merely exemplary of the remainder of the claim, and therefore not required, or (b) a required feature of the claims. Additionally, in claim 8, the phrase "such as" renders the claim indefinite because it is unclear whether the limitations following the phrase are part of the claimed invention. See MPEP § 2173.05(d). Claim Rejections - 35 USC § 101 and/or 112(b) – Non-Statutory Use Claims 35 U.S.C. 101 reads as follows: Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title. The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. Claims 14 and 15 are rejected under 35 U.S.C. 101 because the claimed invention is directed to non-statutory subject matter, as well as rejected under 35 U.S.C. 112(b) as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor, regards as the invention. Claim 14 is drawn to the “use” of a combination comprising component (A) and (B). In this case, the “use” of does not fall within at least one of the four categories of patent eligible subject matter, and fails to recite steps under U.S.C. 101. In addition, claims 14 and 15 are also rejected under 35 U.S.C. 112(b) as being indefinite for reciting a use without any active, positive steps delimiting how this use is actually practiced. See MPEP 2173.05(q). Conclusion No claims are allowed. Contact Information Any inquiry concerning this communication or earlier communications from the examiner should be directed to TIMOTHY R ROZOF whose telephone number is (571)270-5992. The examiner can normally be reached Monday - Friday, 9:00 a.m. -5:00 p.m.. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Andrew Kosar can be reached at (571) 272-0913. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /TIMOTHY R ROZOF/Primary Examiner, Art Unit 1625
Read full office action

Prosecution Timeline

Aug 09, 2024
Application Filed
Jul 28, 2026
Non-Final Rejection mailed — §101, §102, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12698278
PREPARATION OF SUBSTITUTED 1,2-DIAMINOHETEROCYCLIC COMPOUND DERIVATIVES AND THEIR USE AS PHARMACEUTICAL AGENTS
2y 8m to grant Granted Aug 04, 2026
Patent 12691106
TREATING REFRACTIVE DISORDERS BY TARGETING PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR (PPAR) SIGNALING PATHWAY
3y 1m to grant Granted Jul 28, 2026
Patent 12679843
PYRROLOPYRIMIDINE AMINES AS COMPLEMENT INHIBITORS
2y 10m to grant Granted Jul 14, 2026
Patent 12661359
THERAPEUTIC COMBINATIONS OF ROSUVASTATIN AND RESMETIROM FOR THE TREATMENT OF LIVER DISORDERS OR LIPID DISORDERS
2y 10m to grant Granted Jun 23, 2026
Patent 12662462
SALTS OF PYRIDINYLMETHYLENEPIPERIDINE DERIVATIVES AND USES THEREOF
2y 12m to grant Granted Jun 23, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
73%
Grant Probability
97%
With Interview (+23.9%)
2y 0m (~0m remaining)
Median Time to Grant
Low
PTA Risk
Based on 962 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month